PA-KNOPP-BIOSCIENCES
7.9.2021 12:02:05 CEST | Business Wire | Press release
Knopp Biosciences LLC today reported further clinical and biomarker data demonstrating that reduction in eosinophil count by oral dexpramipexole significantly correlated with improved lung function in the positive Phase 2 EXHALE trial of dexpramipexole in patients with moderate-to-severe eosinophilic asthma. The data were presented in a late-breaking abstract session at the European Respiratory Society International Congress 2021.
Eosinophils, a type of white-blood cell, are validated as a therapeutic target in asthma by the regulatory approval of multiple eosinophil-lowering biologics. Treatments approved to date for eosinophilic asthma are monoclonal antibodies requiring injection or infusion; dexpramipexole is administered orally.
The EXHALE trial was a randomized, double-blind, placebo-controlled trial of dexpramipexole in patients with moderate-to-severe asthma and blood absolute eosinophil count (AEC) ≥300/µL. Dexpramipexole study drug at oral doses of 75 mg/day, 150 mg/day, or 300 mg/day was added to standard of care. The primary endpoint was change in AEC from Baseline to Week 12 compared to placebo.
As previously reported, EXHALE met its primary endpoint, demonstrating dose-dependent lowering of eosinophils, with significant reductions in AEC from Baseline to Week 12 at all doses tested (75 mg/day: ratio to Baseline 0.40, p=0.019; 150 mg/day: ratio to Baseline 0.31, p=0.001, and 300 mg/day: ratio to Baseline 0.21, p<0.0001). Dexpramipexole demonstrated a significant, dose-dependent effect on eosinophil lowering by log-linear testing (p<0.001), and a significant increase from baseline in lung function as measured by prebronchodilator FEV1 change (ΔFEV1 +172 mL vs placebo, p=0.015), pooling data across study arms (75 mg/day, 150 mg/day, and 300 mg/day) and visits (Weeks 4, 8, 12, and 16/18).
Today’s presentation to ERS 2021 reported that eosinophil reduction by dexpramipexole significantly correlated with improvement in prebronchodilator FEV1 (combined 300 mg/day and 150 mg/day dexpramipexole, Spearman correlation coefficient -0.58, p<0.0001). FEV1, the amount of air a patient can forcibly exhale in one second, is a fundamental measure of asthma control.
The newly reported results also included the dose-dependent effects of dexpramipexole on nasal eosinophil peroxidase (EPX), a marker of airway eosinophilia associated with mucus plugging and airway trapping in severe asthma .1 In a prespecified analysis, nasal EPX at Week 12 was reduced by 89.0% (p=0.020), 82.6% (p=0.021), 35.5% (p=0.540), and 16.7% for the 300 mg/day, 150 mg/day, 75 mg/day, and placebo arms, respectively (p-values relative to placebo). These results reinforced previous reports showing effective tissue eosinophil lowering by dexpramipexole in chronic rhinosinusitis with nasal polyps and hypereosinophilic syndrome .2,3
“These results add to the body of evidence that dexpramipexole reduces eosinophil burden in affected tissues as well as in blood, and strengthen the hypothesis that reductions in blood and tissue eosinophils by dexpramipexole is associated with improved lung health,” said Michael Bozik, M.D., CEO of Knopp. “As we prepare for entry into Phase 3 clinical trials, the results also reinforce our confidence in the potential of dexpramipexole as the first oral agent that can significantly reduce the risk of exacerbations in eosinophilic asthma.”
As previously reported, dexpramipexole was well tolerated in the EXHALE trial, with no serious adverse events and no adverse events leading to discontinuation. Seventy-four of the 76 dexpramipexole-treated patients completed the primary assessment phase.
ABOUT KNOPP BIOSCIENCES LLC
Knopp Biosciences is a privately held drug discovery and development company focused on delivering breakthrough treatments for immunological and neurological diseases with high unmet need. Knopp’s clinical-stage oral small molecule, dexpramipexole, is in development for moderate-to-severe eosinophilic asthma. Knopp’s preclinical Kv7 platform is directed to small-molecule treatments for developmental and epileptic encephalopathies, other epilepsies, neuropathic pain, and smooth-muscle disorders. Please visit www.knoppbio.com.
ABOUT DEXPRAMIPEXOLE
Dexpramipexole, a selective inhibitor of eosinophil maturation, is an oral small molecule drug in development by Knopp for asthma and other eosinophil-associated diseases. In hypereosinophilic syndrome, dexpramipexole has previously been shown in a Phase 2 trial to significantly reduce requirements for oral corticosteroids and in a subset of patients to produce durable disease remission. In its earlier development in amyotrophic lateral sclerosis, dexpramipexole was shown to be well tolerated in Phase 1, Phase 2, and Phase 3 trials comprising approximately 1,200 patients.
This press release contains "forward-looking statements," including statements relating to planned regulatory filings and clinical development programs. All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including the uncertainties inherent in clinical trials and product development programs, the availability of funding to support continued research and studies, the availability or potential availability of alternative therapies or treatments, the availability of patent protection for the discoveries and strategic alliances, as well as additional factors that may cause Knopp's actual results to differ from our expectations. There can be no assurance that any investigational drug product will be successfully developed or manufactured or that final results of clinical studies will be supportive of regulatory approvals required to market a product. Knopp undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events, or otherwise.
Knopp's pipeline consists of investigational drug products that have not been approved by the U.S. Food and Drug Administration. These investigational drug products are still undergoing pre-clinical or clinical study to verify their safety and effectiveness.
1 Dunican EM et al. J Clin Invest. 2018 Mar 1; 128(3): 997–1009.
2 Laidlaw TM et al. Laryngoscope. 2019 Feb;129(2):E61-E66.
3 Panch SR et al. Blood. 2018 Aug 2; 132(5): 501–509.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210907005172/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Marsh’s Oliver Wyman to Acquire Financial Services and Technology Consultancy Synpulse19.11.2026 14:08:00 CET | Press release
Oliver Wyman, a global leader in management consulting and a Marsh business (NYSE:MRSH), today announced an agreement to acquire Synpulse, a global technology consulting and AI platform company serving banks, insurers, wealth managers and other financial services organizations. Terms of the deal, expected to close in early 2027, were not disclosed. Banks, insurers and asset managers face significant changes driven by advances in technology, data and AI, as well as evolving business models. As these changes accelerate, clients are looking for partners who can help them navigate every stage of transformation, from strategy to technology implementation and execution. Oliver Wyman and Synpulse have already been working together with combined teams on multiple end-to-end transformations for our clients. The acquisition will enable the two businesses to continue to work closely together, combining complementary capabilities and teams to service clients across strategy, technology and impleme
GE HealthCare’s Phase 2 Results Support Advancement of Investigational Manganese-Based MRI Contrast Agent Mangaciclanol Into Phase 3 of LUMINA Clinical Trial19.11.2026 14:00:00 CET | Press release
Key milestone in GE HealthCare’s adaptive Phase 2/3 LUMINA clinical trial, with Phase 2 results meeting primary endpoint, showing mangaciclanol and market-leading gadolinium-based agent, gadobutrol, have similar overall diagnostic preference Mangaciclanol was well tolerated in the Phase 2 stage, with no safety concerns identified following its administration Mangaciclanol has received FDA Fast Track designation, recognizing its potential to address significant unmet patient needs; approximately 65 million gadolinium-enhanced MRI procedures are performed each year GE HealthCare to present preliminary Phase 2 results at RSNA 2026 (Industry Expert Theater) GE HealthCare (Nasdaq: GEHC) today announced Phase 2 results support advancement into Phase 3 for its international, multicenter LUMINA trial of mangaciclanol, with a dose selection of 0.1mmol/kg. Mangaciclanol is an investigational manganese-based magnetic resonance imaging (MRI) contrast agent (MBCA). If approved, MBCAs could offer an
Stronghold Joins the World Economic Forum's New Champions Community19.11.2026 14:00:00 CET | Press release
Stronghold, a fintech infrastructure company, today announced that it has joined the World Economic Forum’s New Champions Community. The New Champions Community is the World Economic Forum’s global network of mission-driven companies, drawn from more than 40 countries and 20 industries. Its work centers on how businesses anticipate change, adapt to disruption and build resilience. Stronghold provides payments infrastructure for merchants and the banks that serve them. The company carries the compliance work that allows banks to serve licensed businesses they would otherwise decline, and makes that work visible to every party in a transaction. That is where resilience gets tested: whether money keeps moving when a market shifts, a rule changes or a bank revisits its risk appetite. “The New Champions Community reflects the values we care about: trust, compliance, and financial innovation,” said Tammy Camp, CEO of Stronghold. “Joining gives us the chance to learn from leaders in industrie
Ehime CATV expands public-sector connectivity in Japan with Adtran XGS-PON technology19.11.2026 14:00:00 CET | Press release
News summary: Ehime CATV needed a compact access platform to connect schools and municipal facilities without large shelf-based infrastructure Adtran’s XGS-PON technology enables the regional service provider to deliver 10Gbit/s connectivity through a scalable architecture The project creates a practical route beyond legacy EPON access networks while mitigating geopolitical supply chain risk Adtran today announced that Ehime CATV has selected its XGS-PON technology to support a new broadband network for public schools and local government offices in Ehime Prefecture, Japan. The deployment will provide 10Gbit/s connectivity to more than 100 public-sector sites, supporting digital learning, cloud-based applications and everyday online services for students, teachers and municipal users. With its compact footprint and flexible expansion model, Adtran’s access technology will help Ehime CATV transition beyond legacy EPON infrastructure to ITU-based XGS-PON. The upgrade will also support a
Update Settlement Infrastructure for New Games, Build Multi-Rail Trust Layer, and Close the Accessibility Gap in AI Economy: Ant International’s Peng Yang at SFF 202619.11.2026 13:05:00 CET | Press release
Speaking at the 2026 Singapore FinTech Festival, Ant International’s CEO Peng Yang argued that our settlement infrastructure needs to evolve beyond today’s four-party payments model to assign effectively roles and responsibilities.Ant International processed the equivalent of 1.1 trillion USD on its WhaleRTP blockchain settlement network in the last 12 months in collaboration with 23 leading global banks; expected to double in 2027.He also said that agentic economy needs to rest on a stronger multi-rail, multi-modal and multi-asset trust layer, and that good AI solutions design can power a new, more inclusive globalization project by putting the little guys on a level playing field. At the Singapore FinTech Festival, Ant International CEO Peng Yang (YP) joined Javier Pérez-Tasso of Swift and Surendra Rosha of HSBC on the panel “From Digital to Intelligent: Who Will Build the Next Financial System?”, moderated by Arjun Vir Singh of Arthur D. Little. This press release features multimedi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
